Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00BMC3RJ87 ORD GBP 0.0125
  Price Change % Change Share Price Shares Traded Last Trade
  2.50 1.25% 202.50 24,369 10:28:04
Bid Price Offer Price High Price Low Price Open Price
200.00 205.00 202.50 200.00 200.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.72 -0.05 138
Last Trade Time Trade Type Trade Size Trade Price Currency
11:17:13 O 502 202.00 GBX

Sareum (SAR) Latest News

More Sareum News
Sareum Investors    Sareum Takeover Rumours

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date Time Title Posts
30/6/202211:23Sareum 2015 11,085
05/8/202108:49No more rns until current project closed-
04/7/202120:52SAR 2013 , SHORT THE ARSE OUT OF IT THREAD326
08/1/202118:09SAR - Sareum Holdings drug discovery370
12/10/202012:29Positive Leukaemia Model19

Add a New Thread

Sareum (SAR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
10:17:15202.005021,014.04O
10:11:48201.001,0002,010.00O
09:54:14202.3353107.23O
09:52:18203.941,5003,059.10O
09:28:57204.964,0008,198.40O
View all Sareum trades in real-time

Sareum (SAR) Top Chat Posts

DateSubject
30/6/2022
09:20
Sareum Daily Update: Sareum Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 200p.
Sareum Holdings Plc has a 4 week average price of 162.50p and a 12 week average price of 140p.
The 1 year high share price is 487.50p while the 1 year low share price is currently 84.60p.
There are currently 68,069,416 shares in issue and the average daily traded volume is 68,604 shares. The market capitalisation of Sareum Holdings Plc is £137,840,567.40.
28/6/2022
18:38
criticalthinker1: Oh my re the posts today. Anyhows...genuine query..why has there been RNS silence since this last one? Tue, 26th Apr 2022 07:00 RNS Number : 2523J Sareum Holdings PLC 26 April 2022 Sareum Holdings plc ("Sareum" or the "Company") Sareum to Present at BioTrinity 2022 Conference Cambridge, UK, 26 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a Company Showcase presentation at the BioTrinity 2022 conference, being held in London on 26 and 27 April. In his presentation, Dr Mitchell will provide updates on the progress of Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801, targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections; and SDC-1802, targeting cancers. If you look at NDAs it is rather interesting how the background legalities allow them to NOT have to always report them due to 'shareholder best interests' due to ongoing sensitive details that would/might negatively affect the potential deal. Just saying 2 months of silence, no 'dutiful' RNS required obligation to update shareholders on updated march 2022 report on SRA737 INHUMAN trials in the public domain. Anyone think they are going to release a RNS that updates on operations and finances and just gives minor references to our ipr outside of our control and state 1801 into trials? Regards Steadydanny
27/6/2022
08:30
gekko2023: Annnnddddd..the share price falls again...MrsRapesLapdog...DarkPoo..anything you would like to add...ahouldnt our share price be rising giving the imminent takeover? xx
25/6/2022
19:39
criticalthinker1: Trying to understand this comment from Tim 6th August last year... Sareum’s CEO, Dr Tim Mitchell, commented: “It is encouraging to note from Sierra’s investor call that, while it has made no commitment towards the further development of SRA737, it sees further potential opportunities for this novel agent following the addition of AZD5153 into its pipeline. We remain optimistic that Sierra will find a solution to advance development of the SRA737 programme in the future.” The plot thickens given that SO have continued 737 trials. Anyone remember the squeaky chair scenario? Lol. Monday imo is share price breakout day. There have been days where 50k total value trades were occurring for a period...then it slowed...but probably assisted by PH having access to a BODS share sell and weakened holders and stop losses. Monday is going to be very interesting especially if Norma is correct about 737 being inhuman trialled in countries that do not qualify our payment. And let's not forget the ongoing patents. Booooooooooooooom! Steadydanny They are
22/6/2022
16:36
gekko2023: HorridHenry, I think he's actually damaged you...its like you are his number 1 cheerleader. Look at the share price. Look at it for today .the last 5 days...year to date.. this is a nonsense...and yet the Froth worshipping simps on LSE are all talking TO of 10x share price...or holiday destinations...embarrassing. X
14/6/2022
22:28
criticalthinker1: If people are having trouble joining the dots then this from July 21 US Patent Notice of Allowance for Sareum's SDC-1802 Cambridge, UK, 30 July 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the "SDC-1802 Programme"). The patent (US Patent Application no. 16/343,639) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development. The Company expects that the patent will be granted within three months, subject to certain formalities being completed Please read the first paragraph slowly. Pound to a penny its Kowalski at SO when he was possibly there utilising 1802 (very similar to 1801) with AZD5153 or SRA737 or momo.... and hence the US Patent. So we have 1801 going to CTA and 1802 as a side order being used as A Notice of Allowance as an invention associated with our proprietary 1802!!! And we have 1801 oven ready for CTA and tox approved which has HNWI backing which 1802 benefits from any of our research. Win win! Anyone think we have the golden carrot that we have in front of GSK et al and we are on the cusp of something extraordinary!? I think our board are going to be billionaires! Regards CT.
27/5/2022
19:11
criticalthinker1: Hi Silver. Have a great getaway. Word of advice re fuel. Don't use E10 in your vehicle or garden machinery. Because its 10% ethanol it draws moisture and affects o rings etc that are plastic based which then degrade. Second point. What's your opinion on the share price staying stagnant yet the buys are extremely superior? Do you think PH are buying what they can and filling iis fill orders. Surely given the time this has been going on a TR1 is incoming given just over 2m shares required. Makes me think about some holders who claim to hold certain large volumes yet have not been mentioned in a TR1! Maybe the 29m share option 'thanks' to 'introducers' which can be purchased when share price hits x but post consolidation equates to 580k, Something is happening. Those continued buys before would have seen a significant share price rise. I'm waiting for the big bang. Q3? ;-) ? Anyhows have a great holiday. CT
13/4/2022
16:16
bountyhunter: 13/04/2022 4:00pm RNS Number : 3162I SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sareum notes proposed acquisition of Sierra Oncology by GSK Cambridge, UK, 13 April 2022 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, notes that Sierra Oncology, Inc ("Sierra"), the licence holder for SRA737 (a novel Chk1 inhibitor), has agreed to be acquired by GlaxoSmithKline plc ("GSK") for US$1.9 billion in cash. The transaction is expected to close in the third quarter of 2022 or before. GSK has noted that the key driver of the acquisition was momelotinib, a drug Sierra is developing for the treatment of myelofibrosis, which reported positive topline results in a Phase III study in January 2022. SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed to Sierra in September 2016. During the second half of 2021 and early 2022, Sierra noted it is finalising the design of several potential clinical trials to advance its pipeline candidates, including SRA737, which it said could start in 2022. These trials would investigate SRA737 in combination with other agents in haematologic and solid tumour indications. Under an amended US$299m licensing deal on SRA737 between Sierra and CRT Pioneer Fund LP, Sareum is eligible to receive a 27.5% share of any future milestone payments as well as royalties on any future sales. The dosing of the first patient with SRA737 in any new clinical trial would result in a US$2.0m payment from Sierra, with 27.5% of this due to Sareum.
15/3/2022
22:04
spacedust: I always said IF bill gates....etc Yes i was all for this prior to consol and stand by those price targets. But post consol i have lost faith. Company may do well. But share price will die. Watch and see the death of share price Old 9p is todays 450p. Old 28p target is todays stonking 1400p. Never going to happen
17/2/2022
13:29
spacedust: Silver...yes ive made the best returns from sar than i have from any other aim share. Hence why ive always been supportive. Ive been negative since th3 consolidation news because from my experience of 15yrs trading in aim, consolidation has always, for me personally, been the death of share price and ive given examples of.... Aston martin Edl Songbird estates Ntog There are tonnes more. You will struggle to find at least 5 aim companies in the past 10 yrs who've consolidated and it then worked out better for share price However i can name you 10 companies in a matter of seconds from memory where consolidation has been the death of the share price I still hold half but will sell more over 6p if it suddenly rises but will always keep 25%
16/12/2021
10:01
spacedust: I'll sell just before consolidation. Hope there is a spike for no reason to 10p just before consolidation At 5p right now the share price could easily multi bag to 50p on sudden good news If it's 100 to 1 consolidation the new price will be 500p area if we are to go by today's share price What are the chances of the share price then going from 500p to 5000p? Highly unlikely. 5p to 50p is very feasible.
Sareum share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
SAR
Sareum
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220630 10:42:00